Genetic and immunologic susceptibility to statin-related myopathy

Jaideep Patel, H. Robert Superko, Seth S. Martin, Roger S. Blumenthal, Lisa Christopher-Stine

Research output: Contribution to journalReview article

Abstract

Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM.

Original languageEnglish (US)
Pages (from-to)260-271
Number of pages12
JournalAtherosclerosis
Volume240
Issue number1
DOIs
StatePublished - May 1 2015

Keywords

  • Anti-HMGCR
  • Pharmacogenomics
  • SLCO1B1
  • Statin-related myopathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Genetic and immunologic susceptibility to statin-related myopathy'. Together they form a unique fingerprint.

  • Cite this